## David L Bartlett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8664630/publications.pdf

Version: 2024-02-01

160 papers 8,283 citations

57719 44 h-index 84 g-index

167 all docs

167 docs citations

times ranked

167

10641 citing authors

#	Article	IF	CITATIONS
1	Ferroptosis Inducer Improves the Efficacy of Oncolytic Virus-Mediated Cancer Immunotherapy. Biomedicines, 2022, 10, 1425.	1.4	11
2	Time to Surgery and Colon Cancer Survival in the United States. Annals of Surgery, 2021, 274, 1025-1031.	2.1	47
3	Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Therapy, 2021, 28, 98-111.	2.2	30
4	Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case–Control Matched Analysis. Annals of Surgical Oncology, 2021, 28, 3779-3788.	0.7	12
5	Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer. Translational Research, 2021, 229, 100-114.	2.2	6
6	2020 SSO Presidential Address: Surgical Oncology Moonshot. Annals of Surgical Oncology, 2021, 28, 585-593.	0.7	0
7	500 Minimally Invasive Robotic Pancreatoduodenectomies. Annals of Surgery, 2021, 273, 966-972.	2.1	112
8	Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. Annals of Surgical Oncology, 2021, 28, 3800-3807.	0.7	11
9	Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases. Annals of Surgical Oncology, 2021, 28, 4637-4646.	0.7	13
10	In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy. Frontiers in Immunology, 2021, 12, 610042.	2.2	6
11	A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Annals of Surgical Oncology, 2021, 28, 2438-2446.	0.7	16
12	IL- $36\hat{l}^3$ -armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity. Cancer Immunology, Immunotherapy, 2021, 70, 2467-2481.	2.0	13
13	Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies. Annals of Surgical Oncology, 2021, 28, 2715-2727.	0.7	11
14	ASO Visual Abstract: A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Annals of Surgical Oncology, 2021, 28, 2449-2450.	0.7	1
15	Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma. Journal of Surgical Oncology, 2021, 124, 308-316.	0.8	9
16	Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 7759-7769.	0.7	8
17	Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut, 2020, 69, 52-61.	6.1	108
18	Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection. Annals of Surgical Oncology, 2020, 27, 107-114.	0.7	4

#	Article	IF	CITATIONS
19	Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience. Annals of Surgical Oncology, 2020, 27, 147-153.	0.7	31
20	Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas andÂBile Duct. Gastroenterology, 2020, 158, 573-582.e2.	0.6	110
21	Defining and Refining the Role for Surgery and Intraperitoneal Chemotherapy in the Treatment of Peritoneal Surface Malignancies. Annals of Surgical Oncology, 2020, 27, 73-75.	0.7	2
22	Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. Annals of Surgical Oncology, 2020, 27, 772-780.	0.7	20
23	Better Biomarkers for Surgeons Treating Cancer. JAMA Surgery, 2020, 155, 580.	2.2	0
24	BAX-dependent mitochondrial pathway mediates the crosstalk between ferroptosis and apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2020, 25, 625-631.	2.2	51
25	Changes in Performance of More Than 1000 Minimally Invasive Liver Resections. JAMA Surgery, 2020, 155, 986.	2.2	9
26	Synergistic apoptosis following endoplasmic reticulum stress aggravation in mucinous colon cancer. Orphanet Journal of Rare Diseases, 2020, 15, 211.	1.2	6
27	In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2. Molecular Therapy - Oncolytics, 2020, 17, 350-360.	2.0	23
28	KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. Modern Pathology, 2020, 33, 1832-1843.	2.9	18
29	COVID-19 Guideline Modifications as CMS Announces "Opening Up America Again†Comments from the Society of Surgical Oncology. Annals of Surgical Oncology, 2020, 27, 2111-2113.	0.7	6
30	Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status. American Journal of Surgical Pathology, 2020, 44, 991-1001.	2.1	15
31	Clinicopathological analysis of appendiceal goblet cell adenocarcinoma with peritoneal metastasis: World Health Organization grade predicts survival following cytoreductive surgery with intraperitoneal chemotherapy. Histopathology, 2020, 77, 798-809.	1.6	10
32	Longâ€ŧerm survival following minimally invasive extended cholecystectomy for gallbladder cancer: A 7â€year experience from the National Cancer Database. Journal of Surgical Oncology, 2020, 122, 707-715.	0.8	7
33	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clinical Cancer Research, 2020, 26, 3126-3134.	3.2	133
34	Ferroptotic agentâ€induced endoplasmic reticulum stress response plays a pivotal role in the autophagic process outcome. Journal of Cellular Physiology, 2020, 235, 6767-6778.	2.0	26
35	Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors. Cancer Medicine, 2020, 9, 1753-1767.	1.3	9
36	Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma. Clinical Cancer Research, 2020, 26, 2216-2230.	3.2	39

#	Article	IF	CITATIONS
37	Longâ€ŧerm oncologic outcomes of robotic and open pancreatectomy in a national cohort of pancreatic adenocarcinoma. Journal of Surgical Oncology, 2020, 122, 234-242.	0.8	47
38	Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. , 2020, 8, e000710.		43
39	Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 2961-2971.	0.7	8
40	Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations. Annals of Surgical Oncology, 2020, 27, 1717-1720.	0.7	180
41	A Real-Time Mobile Intervention to Reduce Sedentary Behavior Before and After Cancer Surgery: Usability and Feasibility Study. JMIR Perioperative Medicine, 2020, 3, e17292.	0.3	23
42	Deciphering the Molecular Landscape of Appendiceal Mucinous Neoplasms for Diagnostic, Prognostic and Therapeutic Purposes. Annals of Surgical Oncology, 2020, 27, 1312-1313.	0.7	0
43	Significance of Uncinate Duct Dilatation in IPMNs. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	1
44	ASO Author Reflections: Controversies and Confusion in Terminology and Grading of Primary Appendiceal Mucinous Neoplasms. Annals of Surgical Oncology, 2019, 26, 776-777.	0.7	0
45	Neutrophil Extracellular Traps Drive Mitochondrial Homeostasis in Tumors to Augment Growth. Cancer Research, 2019, 79, 5626-5639.	0.4	129
46	Discordant Diagnostic Terminology and Pathologic Grading of Primary Appendiceal Mucinous Neoplasms Reviewed at a High-Volume Center. Annals of Surgical Oncology, 2019, 26, 2607-2614.	0.7	14
47	It Is Time. Annals of Surgical Oncology, 2019, 26, 1963-1966.	0.7	0
48	Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases. Annals of Surgical Oncology, 2019, 26, 1445-1453.	0.7	26
49	Discrimination of low- and high-grade appendiceal mucinous neoplasms by targeted sequencing of cancer-related variants. Modern Pathology, 2019, 32, 1197-1209.	2.9	13
50	<p>A cautionary note on the selectivity of oncolytic poxviruses</p> . Oncolytic Virotherapy, 2019, Volume 8, 3-8.	6.0	14
51	Ferroptosisâ€inducing agents enhance TRAILâ€induced apoptosis through upregulation of death receptor 5. Journal of Cellular Biochemistry, 2019, 120, 928-939.	1.2	51
52	Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures. JAMA Network Open, 2019, 2, e186847.	2.8	137
53	Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics., 2019, 7, 6.		190
54	Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2019, 26, 1429-1436.	0.7	7

#	Article	IF	CITATIONS
55	Crosstalk Between Apoptosis and Autophagy Is Regulated by the Arginylated BiP/Beclin-1/p62 Complex. Molecular Cancer Research, 2018, 16, 1077-1091.	1.5	35
56	Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE. Annals of Surgical Oncology, 2018, 25, 1668-1675.	0.7	29
57	Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. Nature Protocols, 2018, 13, 335-357.	5.5	32
58	PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Annals of Surgical Oncology, 2018, 25, 674-678.	0.7	34
59	JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Gastroenterology, 2018, 154, 1480-1493.	0.6	105
60	Ferroptosis-Induced Endoplasmic Reticulum Stress: Cross-talk between Ferroptosis and Apoptosis. Molecular Cancer Research, 2018, 16, 1073-1076.	1.5	233
61	Factors associated with prolonged hospitalization in patients undergoing pancreatoduodenectomy. American Journal of Surgery, 2018, 215, 636-642.	0.9	6
62	Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. Gut, 2018, 67, 2131-2141.	6.1	271
63	Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM). Annals of Surgical Oncology, 2018, 25, 550-557.	0.7	14
64	Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. Annals of Surgical Oncology, 2018, 25, 1094-1100.	0.7	14
65	Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2018, 25, 76-82.	0.7	33
66	Surgical Resection Does Not Improve Survival in Multifocal Intrahepatic Cholangiocarcinoma: A Comparison of Surgical Resection with Intra-Arterial Therapies. Annals of Surgical Oncology, 2018, 25, 83-90.	0.7	50
67	CDK8 Expression in Extrauterine Leiomyosarcoma Correlates With Tumor Stage and Progression. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 161-164.	0.6	3
68	Fitbit step counts during inpatient recovery from cancer surgery as a predictor of readmission. Annals of Behavioral Medicine, 2018, 52, 88-92.	1.7	74
69	Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nature Communications, 2018, 9, 4682.	5.8	59
70	Gasless Transaxillary Endoscopic Thyroidectomy with Robotic Assistance: A High-Volume Experience in North America. Thyroid, 2018, 28, 1655-1661.	2.4	20
71	Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal Malignancies. Annals of Surgical Oncology, 2018, 25, 3950-3959.	0.7	32
72	Together We Make a Difference. Annals of Surgical Oncology, 2018, 25, 1794-1796.	0.7	0

#	Article	IF	CITATIONS
73	Helicase-Driven Activation of NFîºB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment. Cancer Research, 2018, 78, 4292-4302.	0.4	30
74	Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade. Molecular Therapy, 2018, 26, 2476-2486.	3.7	107
75	Evolution of a Novel Robotic Training Curriculum in a Complex General Surgical Oncology Fellowship. Annals of Surgical Oncology, 2018, 25, 3445-3452.	0.7	64
76	PARK7 modulates autophagic proteolysis through binding to the N-terminally arginylated form of the molecular chaperone HSPA5. Autophagy, 2018, 14, 1870-1885.	4.3	23
77	Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma. Journal of Surgical Oncology, 2018, 117, 940-946.	0.8	10
78	Effect of cytoreductive surgery and HIPEC on survival in comparison to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups Journal of Clinical Oncology, 2018, 36, 418-418.	0.8	0
79	Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies. Cancer Medicine, 2017, 6, 195-206.	1.3	11
80	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Adolescent and Young Adults with Peritoneal Metastases. Annals of Surgical Oncology, 2017, 24, 875-883.	0.7	8
81	Epinephrine promotes COX-2-dependent immune suppression in myeloid cells and cancer tissues. Brain, Behavior, and Immunity, 2017, 62, 78-86.	2.0	37
82	Liver Resection After Selective Internal Radiation Therapy with Yttrium-90 is Safe and Feasible: A Bi-institutional Analysis. Annals of Surgical Oncology, 2017, 24, 906-913.	0.7	32
83	Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer. Journal of Surgical Oncology, 2017, 116, 320-328.	0.8	11
84	Radiation-Induced Glandular Malignant Peripheral Nerve Sheath Tumor. International Journal of Surgical Pathology, 2017, 25, 635-639.	0.4	2
85	Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). International Journal of Hyperthermia, 2017, 33, 520-527.	1.1	68
86	Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Research, 2017, 27, 916-932.	5.7	103
87	Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nature Communications, 2017, 8, 14754.	5.8	268
88	Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells. Nature Communications, 2017, 8, 14649.	5.8	128
89	Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas. Human Pathology, 2017, 66, 86-92.	1.1	21
90	Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus. Molecular Therapy - Methods and Clinical Development, 2017, 7, 112-122.	1.8	10

#	Article	IF	CITATIONS
91	Institutional Experience with Ostomies Created During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion. Annals of Surgical Oncology, 2017, 24, 3811-3817.	0.7	8
92	Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma. Annals of Surgical Oncology, 2017, 24, 3624-3630.	0.7	24
93	Safety and efficacy of combined resection of colorectal peritoneal and liver metastases. Journal of Surgical Research, 2017, 219, 194-201.	0.8	16
94	Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case–Control Study. Annals of Surgical Oncology, 2017, 24, 150-158.	0.7	37
95	Mucinous and Signet Ring Cell Differentiation Affect Patterns of Metastasis in Colorectal Carcinoma and Influence Survival. International Journal of Surgical Pathology, 2017, 25, 108-117.	0.4	24
96	Oncolytic Virotherapy and the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2017, 1036, 157-172.	0.8	25
97	Editorial of the Special Issue: Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer. Biomedicines, 2017, 5, 52.	1.4	5
98	Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent PUMA expression. Oncotarget, 2017, 8, 115164-115178.	0.8	127
99	Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei. Oncotarget, 2017, 8, 106888-106900.	0.8	19
100	Effect of a concomitant urologic procedure on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Journal of Surgical Oncology, 2016, 113, 218-222.	0.8	11
101	Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology, 2016, 68, 729-737.	1.6	26
102	Secretory TRAIL-Armed Natural Killer Cell–Based Therapy: <i>In Vitro</i> and <i>In Vivo</i> Colorectal Peritoneal Carcinomatosis Xenograft. Molecular Cancer Therapeutics, 2016, 15, 1591-1601.	1.9	10
103	Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Molecular Therapy, 2016, 24, 1492-1501.	3.7	110
104	Safety in Numbers. Surgical Innovation, 2016, 23, 407-414.	0.4	28
105	Robotic and open distal pancreatectomy with celiac axis resection for locally advanced pancreatic body tumors: a single institutional assessment of perioperative outcomes and survival. Hpb, 2016, 18, 835-842.	0.1	62
106	Robotic assisted placement of hepatic artery infusion pump is a safe and feasible approach. Journal of Surgical Oncology, 2016, 114, 342-347.	0.8	14
107	Robotic-Assisted Placement of an Hepatic Artery Infusion Pump and Catheter for Regional Chemotherapy of the Liver. Annals of Surgical Oncology, 2016, 23, 755-756.	0.7	6
108	Deviations from Expected Treatment of Pancreatic Cancer in Octogenarians: Analysis of Patient and Surgeon Factors. Annals of Surgical Oncology, 2016, 23, 4149-4155.	0.7	31

#	Article	IF	CITATIONS
109	Curative Surgical Resection as a Component of Multimodality Therapy for Peritoneal Metastases from Goblet Cell Carcinoids. Annals of Surgical Oncology, 2016, 23, 4338-4343.	0.7	15
110	Regional Therapies for Advanced Cancer: Update for 2016. Annals of Surgical Oncology, 2016, 23, 1452-1453.	0.7	0
111	Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer., 2016, 4, 24.		19
112	TRAILâ€Induced Caspase Activation Is a Prerequisite for Activation of the Endoplasmic Reticulum Stressâ€Induced Signal Transduction Pathways. Journal of Cellular Biochemistry, 2016, 117, 1078-1091.	1.2	11
113	Cancer Stem Cells Protect Nonâ€Stem Cells From Anoikis: Bystander Effects. Journal of Cellular Biochemistry, 2016, 117, 2289-2301.	1.2	32
114	Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Patients with High-Grade, High-Volume Disseminated Mucinous Appendiceal Neoplasms. Annals of Surgical Oncology, 2016, 23, 382-390.	0.7	23
115	Oncologic Risk Stratification Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Carcinomatosis. Annals of Surgical Oncology, 2016, 23, 1587-1593.	0.7	7
116	CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncolmmunology, 2016, 5, e1091554.	2.1	83
117	Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors. Translational Research, 2016, 169, 19-30.e1.	2.2	25
118	The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Modern Pathology, 2016, 29, 14-24.	2.9	114
119	Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer. Annals of Surgical Oncology, 2016, 23, 655-662.	0.7	27
120	An analysis of risk factors for pancreatic fistula after robotic pancreaticoduodenectomy: outcomes from a consecutive series of standardized pancreatic reconstructions. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 1523-1529.	1.3	40
121	Novel chemokine-like activities of histones in tumor metastasis. Oncotarget, 2016, 7, 61728-61740.	0.8	13
122	Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget, 2016, 7, 22174-22185.	0.8	37
123	Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?. Journal of Gastrointestinal Oncology, 2016, 7, 10-7.	0.6	5
124	Effect of adjuvant (AD) radiotherapy (RT) on outcomes following pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PDA): A margin-stratified analysis Journal of Clinical Oncology, 2016, 34, 311-311.	0.8	0
125	The learning curve for robotic distal pancreatectomy: an analysis of outcomes of the first 100 consecutive cases at a highâ€volume pancreatic centre. Hpb, 2015, 17, 580-586.	0.1	153
126	Robotic pancreaticoduodenectomy in the presence of aberrant or anomalous hepatic arterial anatomy: safety and oncologic outcomes. Hpb, 2015, 17, 594-599.	0.1	24

#	Article	IF	CITATIONS
127	Assessment of Quality Outcomes for Robotic Pancreaticoduodenectomy. JAMA Surgery, 2015, 150, 416.	2.2	301
128	Adrenal Imaging Features Predict Malignancy Better than Tumor Size. Annals of Surgical Oncology, 2015, 22, 721-727.	0.7	9
129	Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 4402-4410.	0.7	187
130	Histologic and Immunohistochemical Alterations Associated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2015, 22, 588-595.	0.7	3
131	Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53. Molecular Cancer Research, 2015, 13, 1533-1543.	1.5	6
132	Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth. Translational Research, 2015, 166, 344-354.	2.2	27
133	HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells. Cellular Signalling, 2015, 27, 293-305.	1.7	41
134	First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity. Molecular Therapy, 2015, 23, 202-214.	3.7	117
135	"Preoperative depressive symptoms, 30-day morbidity and readmission, and overall survival following hyperthermic intraperitoneal chemotherapy with cytoreductive surgery for peritoneal carcinomatosis Journal of Clinical Oncology, 2015, 33, e20586-e20586.	0.8	O
136	Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Frontiers in Oncology, 2014, 4, 74.	1.3	216
137	Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Modern Pathology, 2014, 27, 1521-1539.	2.9	131
138	Intracellular Hmgb1 Inhibits Inflammatory Nucleosome Release and Limits Acute Pancreatitis in Mice. Gastroenterology, 2014, 146, 1097-1107.e8.	0.6	200
139	GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. Human Pathology, 2014, 45, 1737-1743.	1.1	68
140	Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death. Biochemical Pharmacology, 2014, 88, 178-188.	2.0	51
141	Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis. Annals of Surgical Oncology, 2014, 21, 1159-1165.	0.7	87
142	T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy. Molecular Therapy, 2014, 22, 102-111.	3.7	140
143	Preoperative inflammatory biomarkers and neurovegetative symptoms in peritoneal carcinomatosis patients Journal of Clinical Oncology, 2014, 32, e20628-e20628.	0.8	0
144	Oncolytic viruses as therapeutic cancer vaccines. Molecular Cancer, 2013, 12, 103.	7.9	252

#	Article	IF	CITATIONS
145	Extensive Cytoreductive Surgery for Appendiceal Carcinomatosis: Morbidity, Mortality, and Survival. Annals of Surgical Oncology, 2013, 20, 1056-1062.	0.7	35
146	Analysis of toxicity and outcomes in patients undergoing hyperthermic isolated hepatic perfusion with melphalan for metastatic melanoma to the liver Journal of Clinical Oncology, 2013, 31, 178-178.	0.8	0
147	Pancreaticoduodenectomy versus radiosurgery for octogenarians with pancreatic head adenocarcinoma Journal of Clinical Oncology, 2013, 31, 220-220.	0.8	O
148	Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer. Cancer Research, 2012, 72, 1651-1660.	0.4	94
149	NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells. Cancer Research, 2012, 72, 3735-3743.	0.4	119
150	Influence of blood neutrophil to lymphocyte ratio on oncologic outcomes in peritoneal carcinomatosis of appendiceal origin Journal of Clinical Oncology, 2012, 30, e14184-e14184.	0.8	1
151	A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases (ILM) from colorectal cancer (CRC) Journal of Clinical Oncology, 2012, 30, 283-283.	0.8	0
152	Margin distance as an independent predictor of survival after RO resection for pancreatic adenocarcinoma Journal of Clinical Oncology, 2012, 30, 321-321.	0.8	0
153	Can metastatic colorectal cancer be cured?. Oncology, 2012, 26, 266-75.	0.4	20
154	Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer. Molecular Therapy, 2011, 19, 650-657.	3.7	119
155	Induction of CD8 <sup>+</sup> T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. Journal of Clinical Oncology, 2011, 29, 330-336.	0.8	519
156	Aggressive Surgical Management of Peritoneal Carcinomatosis With Low Mortality in a High-Volume Tertiary Cancer Center. Annals of Surgical Oncology, 2008, 15, 754-763.	0.7	156
157	Ability of Mature Dendritic Cells to Interact with Regulatory T Cells Is Imprinted during Maturation. Cancer Research, 2008, 68, 5972-5978.	0.4	161
158	Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement. Annals of Surgical Oncology, 2006, 13, 1284-1292.	0.7	37
159	The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2. Cancer Research, 2005, 65, 9991-9998.	0.4	111
160	Long-Term Follow-Up After Curative Surgery for Early Gastric Lymphoma. Annals of Surgery, 1996, 223, 53-62.	2.1	62